NCT02905318

Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients With Metastatic Castration-Resistant Prostate Cancer

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 19 (actual)
• Sponsor: Canadian Cancer Trials Group · Network
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to find out what effects a new drug, palbociclib, has on prostate cancer and will look at the side effects of treatment with palbociclib. The researchers doing this study are also interested in looking for markers that may help predict which patients are most likely to be helped by palbociclib and to see how the cancer cells respond to palbociclib.

Detailed description

The standard or usual treatment for this disease may be chemotherapy or other types of treatment to slow the spread of the disease and relieve some symptoms of cancer. Palbociclib is a new type of drug for prostate cancer. Laboratory tests show that it may help slow the growth of prostate cancer. Palbociclib has been shown to help patients with breast cancer but it is not known if the drug is useful for treating prostate cancer.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
DRUG	Palbociclib	125 mg orally on days 1-21 each 28 day cycle

Timeline

• Start date: 2017-07-04
• Primary completion: 2022-04-29
• Completion: 2026-12-30
• First posted: 2016-09-19
• Last updated: 2026-03-09

Locations

7 sites across 1 country: Canada